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Effector Tregs: middle-men in TGFβ activation
John J. Worthington and Mark A. Travis
Regulatory T-cells (Tregs) are an inherent 
suppressive cell of the immune system with an established 
developmental requirement for the cytokine transforming 
growth factor β (TGFβ). However, the precise mechanisms 
by which mature Tregs utilize TGFβ during disease 
are unclear. In the May issue of Immunity, we have 
demonstrated that effector regulatory T-cells are essential 
activators of latent-TGFβ which is crucial to suppress 
ongoing inflammation.
A failure to regulate effective immunity results in 
chronic inflammation which can lead to immunopathology 
and carcinogenesis. One of the key molecules involved 
in immune cell suppression is the cytokine TGFβ, which 
crucially must be activated from its latent state in order to 
function [1]. An essential function of TGFβ is to drive the 
development of Tregs, both naturally derived thymic Tregs 
and the peripherally induced Tregs that are converted 
from the naïve T-cell population (pTregs) [2]. This critical 
subset of T-cells with an inherent suppressive role has 
been a huge focus of research both mechanistically and 
therapeutically, with current treatments for autoimmunity 
and transplantation involving the ex vivo expansion of 
patient’s Tregs and conversely selective Treg depletion 
during cancer treatment.
Several in vivo studies have clearly shown that, in 
addition to its role in Treg development, TGFβ plays a 
fundamental role in the suppressive function of Tregs. 
However, the precise mechanisms by which TGFβ 
mediates Treg biology are unclear, with conflicting 
reports existing within the literature, most notably in 
studies utilizing T-cell transfer colitis. Within this colitis 
model, Tregs are essential for the suppression of disease 
but are still able to suppress inflammation when they lack 
the ability to produce TGFβ [3, 4]. However, the use of 
blocking antibodies in the same study demonstrates the 
complete dependence on TGFβ for disease suppression 
[3]. Furthermore, effector T-cells themselves must respond 
to TGFβ for Treg-mediated prevention of colitis, as T-cells 
require functional TGFβ receptors to be supressed [3]. 
Collectively, these data indicate that TGFβ is absolutely 
required for Tregs to suppress effector T-cells, but Tregs 
themselves do not need to be the source of TGFβ. 
A particular focus within the Mark Travis lab at 
the Manchester Collaborative Centre for Inflammation 
Research, University of Manchester, is the regulation of 
latent TGFβ during intestinal inflammation. The TGFβ1 
gene (TGFβ1 being the predominate isoform produced 
by the immune system) encodes latency associated 
peptide (LAP), which after transcription remains non-
covalently bound preventing the active TGFβ dimer 
engaging its receptor. This so called LAP “straight-
jacket” that surrounds the TGFβ dimer contains an RGD 
motif which can be bound by αv integrins allowing either 
conformational or protease dependent activation of latent 
TGFβ [1]. We have previously shown that tolerogenic 
CD103+ intestinal dendritic cells, which are key inducers 
of pTregs, are rich in the integrin αvβ8 and it is essential 
for their ability to activate latent TGFβ  and convert naïve 
T-cells into pTregs [5]. A lack of this key regulatory 
molecule on DCs leads to an enhanced ability to fend 
off intestinal infection [6] but mice succumb to an age-
related colitis [7]. We therefore postulated that, rather 
than produce TGFβ, Tregs may be required to activate the 
latent form to drive suppression. 
We now demonstrate high levels of β8 integrin 
gene expression within the Treg population and utilising 
an active TGFβ reporter assay show that Tregs do indeed 
demonstrate an enhanced ability to activate latent TGFβ 
compared to other T-cell subsets. Furthermore, αvβ8 null 
Tregs lose their ability to activate latent TGFβ, suggesting 
that Treg cells activate enhanced levels of TGF-β versus 
other T cell subsets via expression of the integrin αvβ8.
Interestingly, we identified activated effector Tregs, 
thought to regulate ongoing inflammation, as the highest 
expressers of β8 integrin, indicating that this pathway 
maybe important in ongoing inflammation rather than 
homeostasis. As hypothesised, mice lacking β8 integrin 
expression specifically in Tregs (via Foxp3-cre), showed 
no overt autoimmune phenotype even after ageing, and 
Tregs lacking β8 integrin were capable of preventing the 
development of inflammatory T-cells in the intestine when 
co-transferred with effector T-cells in the transfer colitis 
model. Collectively, indicating TGF-β activation by Treg-
cell-expressed integrin αvβ8 is not required for Treg-cell-
mediated control of T cell tolerance at rest. 
In order to examine the role during ongoing 
inflammation we returned to the T-cell transfer colitis 
model. In stark contrast to the co-transfer experiments, 
unlike control Tregs, Tregs that lacked β8 integrin 
expression completely lost their ability to cure colitis when 
transferred after effector T-cells had established ongoing 
inflammation. Moreover, when we examined the differing 
Treg and effector T-cell populations for downstream 
TGFβ signalling in the form of Smad2 phosphorylation, 
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we saw that an increase in TGFβ signalling within the 
colitis-driving effector T-cell population correlated with 
suppression by Tregs. Importantly this increase was 
completely absent when the Tregs attempting to rescue 
colitis lacked β8 integrin expression, demonstrating that 
integrin αvβ8-mediated TGFβ activation by effector 
Tregs is essential for suppression of T-cell mediated 
inflammation. Finally, high expression of β8 integrin 
was also seen in human samples upon examination of the 
equivalent effector Treg populations.
This highlights a new suppressive mechanism 
by which Tregs control ongoing inflammation and is a 
pathway that can hopefully be targeted to prevent chronic 
inflammation, opening up the potential of therapy for a 
variety of inflammatory and autoimmune diseases via the 
manipulation of integrin αvβ8.
“Integrin αvβ8-Mediated TGF-β Activation by 
Effector Regulatory T Cells Is Essential for Suppression 
of T-Cell-Mediated Inflammation” was recently published 
in Immunity: 2015 May 19;42(5):903-15. 
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